var _paq = window._paq = window._paq || []; /* tracker methods like "setCustomDimension" should be called before "trackPageView" */ _paq.push(['trackPageView']); _paq.push(['enableLinkTracking']); (function() { var u=""; _paq.push(['setTrackerUrl', u+'matomo.php']); _paq.push(['setSiteId', '1']); var d=document, g=d.createElement('script'), s=d.getElementsByTagName('script')[0]; g.async=true;'//'; s.parentNode.insertBefore(g,s); })();

Insight | 2021 End of Year Summary

[Click on the image to return to the monthly report index page]


A tangible example of how real world evidence (RWE) can be used to support label extensions for existing drugs.

Note the FDA’s emphasis on:

“This approval reflects how a well-designed, non-interventional study relying on fit-for-purpose real-world data (RWD), when compared with a suitable control, can be considered adequate and well-controlled under FDA regulations”

Hopefully, we will see similar approvals in Europe and the rest of the World

12 January 2021 – At lot happened in the second half of 2021 with respect to new real world research guidelines and regulations.

Most notably in the second half of 2021, we’ve seen guidance published by regulators (EMA, FDA and MHRA) on their expectations when applicants use real world data (RWD) and real world evidence (RWE) to support regulatory decisions, such as marketing authorisation applications (MAAs and NDAs) and label extensions.

The various guidelines (see below) include expectations with regards to the design, conduct and oversight of non-interventional studies and cover elements such as data access contracts, data standards, data integrity, audit trails, 21 CFR 11 compliance, risk-based quality management, monitoring, safety reporting and posting on

Significant updates in the second half of 2021, included:

    • New regulations and guidelines with direct applicability to real world research (Bulgaria, EU, Spain)
    • Changes to research ethics committee online application tools (France, New Zealand)
    • New research transparent requirements (UK)
    • National laws supplementing the EU Medical Devices Regulation (Denmark, Finland, Hungary)

Moderate updates in the second half of 2021, included:

    • New or revised national legislation or guidelines (Argentina, Canada, India, Norway, Poland, UK)
    • Updates to research Ethics committee/ institutional review board policies, procedures and guidelines (Bulgaria, Croatia, Latvia, UK)
    • Updated requirements for post-marketing surveillance studies (Australia)
    • New guidelines for registries and registry-based studies (EU, USA)
    • Guidance/draft guidance on the use of RWD and RWE to support regulatory decisions (UK, USA)
    • Informed consent (Latvia, Spain)
    • Revised NIS reporting requirements (UK)
    • Medical Devices (EU, Hungary, Lithuania, UK)
    • Digital Health Technology (USA)
    • Artificial Intelligence (USA)
    • Big Data (EU)

Minor updates in the second half of 2021, included:

    • New or revised legislation or guidelines (Brazil, Canada, EU, France, Norway, UK, USA)
    • General regulator updates (Australia, Finland, Germany, Hungary, USA)
    • Regulatory decisions based on RWE (USA)
    • Updates to research Ethics committee/ institutional review board policies, procedures and guidelines (Brazil, Bulgaria, Germany, Hong Kong, Hungary, Ireland, Lithuania, New Zealand, Norway)
    • Updates to pharmacoepidemiology guidelines (EU)
    • Data privacy and data access (Norway, UK)
    • Medical devices (EU, Switzerland, UK, USA)
    • ICMJE recommendations for publication of research results in journals (Global)
    • Revision 1 of ICH E8 (Global)

Full details of the real world research regulatory updates in the second half of 2021 can be found in our ‘H2 2021 Summary Report’.

Related Posts

RWR CONTEXT At first glance, the General Practice Data for Planning and Research (GPDPR) seems innocuous. The UK’s NHS is making GP patient data available for research purposes. What isn’t made clear, is that this is an ‘opt out’ [...]

RWR CONTEXT The EMA references this standard in the context of non-interventional post-authorisation safety studies (PASS) as: “Relevant scientific guidance should be considered [= Recommendation, not a legal mandate] by marketing authorisation holders and investigators for the development of [...]

Go to Top